Johnson S, Sommer N, Cox-Flaherty K, et al. Pulmonary hypertension: a contemporary review. Am J Respir Crit Care Med. 2023;208(5):528–48.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kolb M, Orfanos SE, Lambers C, et al. The antifibrotic effects of inhaled treprostinil: an emerging option for ILD. Adv Ther. 2022;39(9):3881–95.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chin KM, Gaine SP, Gerges C, et al. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J. 2024;64(4):2401325.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618–731.

Article  PubMed  CAS  Google Scholar 

Vizza CD, Lang IM, Badagliacca R, et al. Aggressive afterload lowering to improve the right ventricle: a new target for medical therapy in pulmonary arterial hypertension? Am J Respir Crit Care Med. 2022;205(7):751–60.

Article  PubMed  CAS  Google Scholar 

Barst RJ, Galie N, Naeije R, Simonneau G, Jeffs R, Arneson C, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006;28(6):1195–203.

Article  PubMed  CAS  Google Scholar 

Benza RL, Gomberg-Maitland M, Naeije R, et al. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. J Heart Lung Transplant. 2011;30(9):982–9.

Article  PubMed  Google Scholar 

Kingman M, Archer-Chicko C, Bartlett M, et al. Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension. Pulm Circ. 2017;7(3):598–608.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Brewer J, Kimber A. Cannabidiol (CBD) for the treatment of subcutaneous treprostinil (Remodulin®) site pain: a case report. Front Med (Lausanne). 2023;13(10):1188083.

Article  Google Scholar 

Coons JC, Miller T, Simon MA, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients transitioned from parenteral or inhaled prostacyclin: case series and treatment protocol. Pulm Circ. 2016;6(1):132–5.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kumar P, Thudium E, Laliberte K, et al. A comprehensive review of treprostinil pharmacokinetics via four routes of administration. Clin Pharmacokint. 2016;55(12):1495–505.

Article  CAS  Google Scholar 

White RJ, Jerjes-Sanchez C, Bohns Meyer GM, et al. Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial. Am J Respir Crit Care Med. 2020;201(6):707–17.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Orenitram US Prescribing Information. United Therapeutics Corporation. Research Triangle Park, NC 27709.

Chakinala MM, Feldman JP, Rischard F, et al. Transition from parenteral to oral treprostinil in pulmonary arterial hypertension. J Heart Lung Transplant. 2017;36(2):193–201.

Article  PubMed  Google Scholar 

Ramani G, Cassady S, Shen E, et al. Novel dose-response analyses of treprostinil in pulmonary arterial hypertension and its effects on six-minute walk distance and hospitalizations. Pulm Circ. 2020;10(3):2045894020923956.

Article  PubMed  PubMed Central  Google Scholar 

McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915–22. https://doi.org/10.1016/j.jacc.2010.01.027.

Article  PubMed  CAS  Google Scholar 

Ramani G, Eggert M, Palevsky HI, Deng C, Thrasher CM, Spikes LA. Dose-response analyses of treprostinil inhalation powder in PAH and its effect on 6MWD. In: Presented at: American Thoracic Society. May 21–24, 2023. Washington, DC

Tyvaso U.S. Prescribing Information. United Therapeutics Corporation. Research Triangle Park, NC 27709.

Tyvaso DPI U.S. Prescribing Information. United Therapeutics Corporation. Research Triangle Park, NC 27709.

Pan IZ, Carey JR, Jacobs JA, et al. Transitioning between prostanoid therapies in pulmonary arterial hypertension. Front Med (Lausanne). 2020;7:81. 2020 Mar 31.

Picken C, Fragkos KC, Eddama M, Coghlan G, Clapp LH. Adverse events of prostacyclin mimetics in pulmonary arterial hypertension: a systematic review and meta-analysis. J Clin Med. 2019;8(4):481.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Skoro-Sajer N, Bonderman D, Wiesbauer F, et al. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. J Thromb Haemost. 2007;5(3):483–9.

Article  PubMed  CAS  Google Scholar 

Mathier MA, McDevitt S, Saggar R. Subcutaneous treprostinil in pulmonary arterial hypertension: practical considerations. J Heart Lung Transplant. 2010;29:1210–7.

Article  PubMed  Google Scholar 

Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med. 2021;384:325–34.

Article  PubMed  CAS  Google Scholar 

Spikes LA, Bajwa AA, Burger CD, et al. BREEZE: open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension. Pulm Circ. 2022;12(2):e12063.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sargent T, Hansen L, Hohsfield R. Transitions between infused and oral prostacyclin pathway agents in pulmonary arterial hypertension: key considerations. Pulm Circ. 2020;10(3):2045894020931324.

Article  PubMed  PubMed Central  Google Scholar 

Nathan SD, Feldman J, Hansdottir S, et al. Safety and feasibility of switching between oral and parenteral treprostinil [abstract]. Am J Respir Crit Care Med. 2013;187:A3276.

Google Scholar 

Wilson M, Tarver J. Transition protocol of inhaled treprostinil to IV treprostinil in pulmonary arterial hypertension patient before surgery. In: Pulmonary Hypertension Professional Network Symposium (PHPN) 2011. Crystal City, VA. Sept 23–24, 2011.

Preston IR, Feldman J, White J, et al. Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial hypertension. Pulm Circ. 2014;4(3):456–61.

Article  PubMed  PubMed Central  Google Scholar 

Gleason JB, Dolan J, Piran P, Rahaghi FF. The rapid initiation, titration, and transition from intravenous to oral treprostinil in a patient with severe pulmonary arterial hypertension. Case Rep Pulmonol. 2015;2015:498981.

PubMed  PubMed Central  Google Scholar 

Felder A, Bakshi S. Transition between SQ, PO, and IV treprostinil: a case report. In: Presented at PHA’s Pulmonary Hypertension Professional Network Symposium. October 5 – 7, 2017. North Bethesda, Maryland. Abstract 1043. https://phassociation.org/wp-content/uploads/2017/04/2017-PHPN-Symposium-Program-Book.pdf. Accessed 22 May 2025.

Fearon-Clarke J, Goldschmidt M, Hollasch K. Successful transition from subcutaneous treprostinil to oral treprostinil in a patient with pulmonary arterial hypertension: a case study. In: Presented at PHA’s International PH Conference and Scientific Sessions. June 29–July 1, 2018. Orlando, Florida. Abstract 1073.

Smith ZR, Kelly B, Awdish RL, Hegab S. Transitioning parenteral or inhaled Treprostinil to oral Treprostinil diolamine: case series and review of the literature. J Pharm Pract. 2018;32(5):599–604.

Article  PubMed  Google Scholar 

Ackerbauer KA, Tandon R. Transition from subcutaneous or inhaled Treprostinil to oral Treprostinil at home in patients with pulmonary arterial hypertension: a retrospective case series. J Pharm Pract. 2017;31(2):163–6.

Article  PubMed  Google Scholar 

Bryan LG, Jonnalagadda AK, Peters LM, et al. Rapid conversion from parenteral to oral treprostinil. In: Presented at PHA’s Pulmonary Hypertension Professional Network Symposium. October 5–7, 2017. North Bethesda, Maryland.

Suliman SA, Smith JS, Mudd L, et al. Transition from parenteral to oral treprostinil: a single center experience [abstract]. Am J Respir Crit Care Med. 2018;197:A5681.

Google Scholar 

Ali R, Kashyap S, LaRoy V, et al. Successful transition from parenteral to oral treprostinil within 24 hours in pulmonary arterial hypertension. Chest. 2019;156(4 Supplement):A1704–5.

Article  Google Scholar 

Jarrett H, Jonnalagadda AK, Liu SD, et al. Rapid transition from parenteral to oral treprostinil in pulmonary hypertension is feasible and safe: a retrospective cohort study [abstract]. J Heart Lung Transplant. 2018;37(4S):S494.

Article  Google Scholar 

Maestas T, Hansen LM, Vanderpool RR, et al. Right ventricular afterload predicts long-term transition from parenteral to oral treprostinil in pulmonary arterial hypertension. Pulm Circ. 2018;8(4):2045894018797270.

Article  PubMed  PubMed Central  Google Scholar 

Balasubramanian VP, Messick CR, Broderick M, Nelsen AC. Dosing characteristics of oral treprostinil in real-world clinical practice. Pulm Circ. 2018;8(2):2045894018770654.